- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.09. | Telescope Innovations Corp.: Telescope Innovations Appoints Vaso Vlachos as Chief Operating Officer | 271 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 2, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a leader... ► Artikel lesen | |
| 14.08. | Vasomedical reports Q2 results | 1 | Seeking Alpha | ||
| 15.05. | Vaso Corporation Announces Financial Results for First Quarter of 2025 | 226 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| 31.03. | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2024 | 196 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services,... ► Artikel lesen | |
| 13.01. | Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors | 164 | GlobeNewswire (Europe) | PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leader in human capital, information technology and MedTech, today announced new executive appointments... ► Artikel lesen | |
| 16.12.24 | Vaso Corporation CEO Reflects on a Year of Growth and Innovation in End-of-Year Letter Setting the Tone for a Promising 2025 | 167 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 NEWS RELEASE PLAINVIEW, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX:... ► Artikel lesen | |
| VASO Aktie jetzt für 0€ handeln | |||||
| 14.11.24 | Vaso Corporation Announces Financial Results for Third Quarter 2024 | 176 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading medtech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,815 | -1,02 % | Die Gewinner im Zoll-Krieg: Almonty Industries, MP Materials, Bayer | Börsenbeben am Freitag: Donald Trump droht wieder mit der Zoll-Keule. Damit reagierte er auf die Ankündigung Chinas, die Exportkontrollen auf Seltene Erden zu erweitern. Doch es gibt auch Gewinner im... ► Artikel lesen | |
| ASTRAZENECA | 144,35 | -0,24 % | Novo Nordisk: Wie Astrazeneca? | Nach Pfizer hat auch der europäisch-schwedische Pharma-Konzern Astrazeneca einen Deal mit der US-Regierung eingefädelt. Demnach sollen Medikamente des Unternehmens nicht teurer sein als in anderen vergleichbaren... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 9,806 | -1,57 % | EyePoint Pharmaceuticals, Inc.: EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema | - DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 - - New preclinical... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 62,82 | +0,32 % | Hedge Fund and Insider Trading News: Scott Bessent, Paul Tudor Jones, Crispin Odey, Ken Griffin, Millennium Management, Ionis Pharmaceutical Inc (IONS), Chicago Atlantic Real Estate Finance Inc (REFI), and More | ||
| CSPC PHARMA | 0,945 | -3,24 % | Dividendenbekanntmachungen (17.10.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACUITY INC US00508Y1029 0,17 USD 0,1454 EUR COLGATE-PALMOLIVE COMPANY US1941621039 0,52 USD 0,4448 EUR CRACKER BARREL OLD COUNTRY... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,904 | +3,59 % | SELLAS to present CDK9 inhibitor data for T-cell leukemia at ESMO | ||
| ACADIA PHARMACEUTICALS | 18,355 | +2,54 % | XFRA DR6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILACADIA PHARMACEUT.... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 17,425 | -1,08 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 375,60 | -0,05 % | AKTIONÄR-Hot-Stock Madrigal: Heißer Markt - Kursziele rauf | Madrigal Pharmaceuticals hat im vergangenen Jahr Geschichte geschrieben. Mit Rezdiffra konnte das US-Unternehmen das erste Medikament überhaupt zur Behandlung der metabolischen Dysfunktion assoziierten... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,056 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Enter into Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., June 20, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQX: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| OPUS GENETICS | 1,622 | +0,62 % | Chardan Capital Markets initiates Opus Genetics stock with Buy rating | ||
| CHUGAI PHARMACEUTICAL | 39,140 | -1,31 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,090 | 0,00 % | NSE - Viracta Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| SAVARA | 2,980 | -3,25 % | Savara Promotes Dr. Yasmine Wasfi to Chief Medical Officer |
VASO CORPORATION gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VASO CORPORATION finden Sie auf Wallstreet Online.